Invitation: Advancing Oncology Care with MRD & Next Generation Diagnostics.During this session, we will discuss how Signatera™ molecular residual disease (MRD) testing is being used to inform treatment decisions, detect recurrence earlier, and support longitudinal surveillance across multiple tumor types. We will also review Empower™ hereditary Cancer Testing.
Presenter: Kyle Duffy, Senior Clinical Oncology Specialist
RSVP TO: kduffy@natera.com
Location: Papadeaux Seafood Kitchen -ABQ (5011 Pan American Hwy NE)